An Extension Study to Provide Bortezomib to Patients With Relapsed or Refractory Multiple Myeloma Who Previously Participated in a Bortezomib Phase I/II Study and Who May Benefit From Re-Treatment With or Continuation of Bortezomib Therapy

This study has been completed.

Sponsor:

Information provided by:

Janssen Pharmaceutical K.K.

ClinicalTrials.gov Identifier:

NCT00216697

First received: September 13, 2005

Last updated: May 16, 2011

Last verified: April 2010

No Study Results Posted on ClinicalTrials.gov for this Study

Study Status:	This study has been completed.
Study Completion Date:	October 2006
Estimated Primary Completion Date:	No date given